Bioventus director receives RSU grant, exercises awards

Bioventus Inc. director William A. Hawkins reported equity compensation activity involving restricted stock units (RSUs) and Class A common stock.

Rhea-AI Filing Summary

Bioventus Inc. director William A. Hawkins reported equity compensation activity involving restricted stock units (RSUs) and Class A common stock. On June 3, 2026, he received a grant of 30,994 RSUs, each representing a contingent right to receive one share of Class A common stock, with vesting tied to continued board service.

On June 2, 2026, 39,789 RSUs vested and were exercised into 39,789 shares of Class A common stock. Following these transactions, Hawkins directly owned 297,640 shares of Class A common stock and held 30,994 RSUs as a separate derivative position, reflecting routine director compensation and vesting rather than open-market trading.

Insider Trade Summary

39,789 shares exercised/converted

Exercise 3 txns

Insider HAWKINS WILLIAM A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	30,994	$0.00	$0.00
Exercise	Restricted Stock Units	39,789	$0.00	$0.00
Exercise	Class A Common Stock	39,789	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 30,994 contracts (Direct); Class A Common Stock — 297,640 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
2. F2. The RSUs vested on June 2, 2026.
3. F3. The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Key Figures

New RSU grant: 30,994 RSUs RSUs exercised: 39,789 RSUs Shares received from exercise: 39,789 shares +2 more

5 metrics

New RSU grant 30,994 RSUs Grant of restricted stock units on June 3, 2026

RSUs exercised 39,789 RSUs Vested and converted to Class A common stock on June 2, 2026

Shares received from exercise 39,789 shares Class A common stock received upon RSU vesting and exercise

Direct common stock holdings 297,640 shares Class A common stock owned directly after transactions

RSUs outstanding after grant 30,994 RSUs Restricted stock units held as derivative position after new award

Key Terms

Restricted Stock Units, Class A Common Stock, Grant, award, or other acquisition, Exercise or conversion of derivative security, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock" with 39,789.0000 underlying shares"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" for the RSU grant"

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security" for the RSU vesting"

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Bioventus (BVS) director William A. Hawkins report?

Bioventus director William A. Hawkins reported equity compensation activity, including a grant of restricted stock units and the vesting and exercise of previously granted RSUs into Class A common stock, with no open-market purchases or sales disclosed in this Form 4.

How many restricted stock units did Hawkins receive from Bioventus (BVS)?

Hawkins received a grant of 30,994 restricted stock units. Each RSU represents a contingent right to receive one share of Bioventus Class A common stock, subject to specific vesting conditions tied to his continued service on the company’s board of directors.

When did William A. Hawkins’ Bioventus RSUs vest and convert to shares?

A block of 39,789 restricted stock units vested on June 2, 2026 and was exercised into 39,789 shares of Bioventus Class A common stock. This conversion reflected previously granted compensation rather than a new open-market stock purchase by the director.

How many Bioventus (BVS) shares does Hawkins hold after these transactions?

After these transactions, Hawkins directly owned 297,640 shares of Bioventus Class A common stock. He also held 30,994 restricted stock units as a derivative position, which may settle into additional shares in the future if vesting conditions are satisfied.

Are Hawkins’ Bioventus (BVS) transactions open-market buys or sells?

The reported transactions are not open-market buys or sells. They consist of a grant of restricted stock units and the vesting and exercise of existing RSUs into Class A common stock, which is standard equity compensation rather than discretionary trading in the public market.

What are the vesting terms for Hawkins’ new Bioventus RSU grant?

The 30,994 RSUs will vest on the earlier of the day immediately preceding Bioventus’ first annual stockholder meeting following the grant date or the first anniversary of the grant date, provided Hawkins continues serving on the company’s board through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS WILLIAM A

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/02/2026		M		39,789	A	$0	297,640	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/02/2026		M			39,789	(2)	(2)	Class A Common Stock	39,789	$0	0	D
Restricted Stock Units	(1)	06/03/2026		A		30,994		(3)	(3)	Class A Common Stock	30,994	$0	30,994	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs vested on June 2, 2026.

3. The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)